DragonWave Agreement With SaaB Equals Huge Stock Opportunity (NASDAQ:DRWI)

DragonWave Inc. (NASDAQ:DRWI)

As the S&P 500 ended on a new all time record high, take a look at DragonWave Inc. ticker symbol DRWI. The Company’s (www.dragonwaveinc.com) stock has surged +16.53% Up 0.20 generating over 2.3 million shares in the financial markets at $1.41 per share Monday December 9, 2013 3:59PM EST. DragonWave Inc. is a leading global supplier of packet microwave radio systems for mobile and access networks. The HOT topic concerning DragonWave Inc. is an agreement concerning an upgrade towards Sweden's national security communication network.

The agreement is with defense and security company Saab to work collaboratively on the expansion and enhancement of national security communication networks in Sweden, Norway, Finland, Denmark and Iceland. The Company reported revenue of $25.5 million for its Q2 2014 which represented a $1 million increase when compared to the year prior. Investors are enticed to consider that DragonWave Inc. balance sheet is truly stabilizing as this Company continues to reduce their operational cost. Agreements like the one mentioned above only increases DragonWave Inc.'s revenue prospects. DragonWave stock price has experienced a +15.57% surge in the stock market concerning its 1 month performance.

****     

Coronado Biosciences, Inc. (NASDAQ:CNDO)

As the November jobs report confirms the economy is improving, check out Coronado Biosciences, Inc. ticker symbol CNDO. The Company’s (www.coronadobiosciences.com) stock has surged +13.37% Up 0.23 generating over 3.8 million shares in the financial markets at $1.95 per share Monday December 9, 2013 3:59PM EST. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The HOT topic concerning Coronado Biosciences is that they submitted an Investigational New Drug application to the U.S. Food and Drug Administration to start a phase 2 study of Trichuris suis ova as a treatment towards chronic plaque psoriasis.

Stock market analytic investors are speculating that the global psoriasis therapeutics market might reach $7.4 billion by 2020. Need we not forget to add, that the Company reported top-line results from the TRUST-I phase 2 clinical trial of Trichuris suis ova or CNDO-201 for the treatment of Crohn's disease. Coronado Biosciences stock price has experienced a +29.29% surge in the stock market concerning its 1 month performance.

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/